The Patent Finder
UD

Universite de Strasbourg

First filing 2002
OverviewNotableFeesChangesFamiliesPatent listSources & methods

81 patents currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
15
Ending by 2030
Dec 2026
Next term end
70
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Pyridazine Compounds, Compositions and Methods US 8,367,672
Cited by 23 later US patents, top 25% of utility patents granted in 2013 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Ends Dec 2029 · High confidence
Also notable
Dynamin 2 Inhibitor for the Treatment of Centronuclear Myopathies US 10,647,986
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Ends Mar 2035 · High confidence
Also notable
Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents US 9,051,302
The largest patent family in this portfolio, 10 related applications, renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Ends Sep 2029 · High confidence

Formerly held, still cited

Notable
Cited by 35 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
Ends Feb 2033 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 3 fees due Dec 6 to 9, 2026 · next Dec 6
  • 2 fees due Jan 11 to 28, 2027 · next Jan 11
  • 1 fee due Apr 3, 2027
    The maintenance fee for Methods and Pharmaceutical Compositions for the Prophylactic Treatment of Metastases (US 11,773,163) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
  • 1 fee due May 21, 2027
    The maintenance fee for Method for Identifying Personalized Therapeutic Strategies for Patients Affected with a Cancer (US 11,823,799) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
  • 2 fees due Jun 5 to 29, 2027 · next Jun 5
  • 1 fee due Jul 23, 2027
    The maintenance fee for Supramolecular Gel Supported on Open-Cell Polymer Foam (US 11,879,038) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.
  • 1 fee due Aug 18, 2027
    The maintenance fee for Fluorescent Compounds of the Boron Thienyldipyrromethene Type, and Their Use (US 10,566,551) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
  • 1 fee due Sep 24, 2027
    The maintenance fee for Method for Chiral Resolution and Device Therefor (US 10,597,339) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
  • 2 fees due Oct 19 to 21, 2027 · next Oct 19
  • 1 fee due Nov 12, 2027
    The maintenance fee for Dynamin 2 Inhibitor for the Treatment of Centronuclear Myopathies (US 10,647,986) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026
  • 1 term has ended since Aug 23, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 9,676,798Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses
In force
 · High confidence
In forceHigh confidence
US 8,163,482BBS10 Related Diagnostic Methods for Bardet-Biedl Syndrome
In force
 · High confidence
In forceHigh confidence
US 9,090,648Cationic Oligonucleotides, Automated Methods for Preparing Same and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 10,239,856Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents
In force
 · Low confidence
In forceLow confidence
US 8,465,920Method for Hybridizing Nucleic Acids
In force
 · High confidence
In forceHigh confidence
US 8,067,412Macrocyclic Compounds Useful as Inhibitors of Kinases and HSP90
In force
 · High confidence
In forceHigh confidence
US 9,051,302Synthesis of Resorcylic Acid Lactones Useful as Therapeutic Agents
In force
 · High confidence
In forceHigh confidence
US 8,351,123Diffractive Head-Up Display Device Provided with a Device for Adjusting the Position of the Virtual Image
In force
 · High confidence
In forceHigh confidence
US 8,476,461Dipyrromethene-Boron Hydrophilic Fluorescent Compounds
In force
 · High confidence
In forceHigh confidence
US 8,367,672Pyridazine Compounds, Compositions and Methods
In force
 · High confidence
In forceHigh confidence
10 of 81 patents shown.
Pro members see all 81.
Pro members: see all 81 patents
Also on record, not counted in the 81: 15 patents in force now held by others · 68 patents ended · 42 applications pending · 121 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited